Clinical Trial Update: Denosumab in Primary Hyperparathyroidism [Phase 4]

View source ↗

Summary

Phase 4 trial update for denosumab in primary hyperparathyroidism has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: Columbia University | Conditions: Primary Hyperparathyroidism | Phase 4 | Status: TERMINATED | Results posted: 2022-11-02